TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 EUR)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
1,688,488
|
1,518,446
|
1,520,399 |
Financial expenses |
44,661
|
44,393
|
59,975 |
Earnings before taxes |
298,428
|
322,190
|
420,125 |
EBITDA |
546,984
|
560,580
|
681,544 |
Total assets |
4,717,342
|
4,758,138
|
4,810,262 |
Current assets |
1,007,432
|
858,325
|
813,748 |
Current liabilities |
1,335,065
|
856,662
|
1,040,399 |
Equity capital |
2,383,563
|
2,268,820
|
2,013,051 |
- share capital |
15,276
|
16,525
|
16,638 |
Employees (average) |
1,556
|
1,559
|
1,509 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
50.5%
|
47.7%
|
41.8% |
Turnover per employee |
1,085
|
974
|
1,008 |
Profit as a percentage of turnover |
17.7%
|
21.2%
|
27.6% |
Return on assets (ROA) |
7.3%
|
7.7%
|
10.0% |
Current ratio |
75.5%
|
100.2%
|
78.2% |
Return on equity (ROE) |
12.5%
|
14.2%
|
20.9% |
Change turnover |
293,037
|
26,205
|
100,922 |
Change turnover % |
21%
|
2%
|
7% |
Chg. No. of employees |
-3
|
50
|
174 |
Chg. No. of employees % |
0%
|
3%
|
13% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.